Intratumoral delivery of dendritic cells plus anti-HER2 therapy triggers both robust systemic antitumor immunity and complete regression in HER2 mammary carcinoma.
Ganesan RamamoorthiKrithika KodumudiColin SnyderPayal GroverHongtao ZhangMark I GreeneAmrita BasuCorey GallenDoris WienerRicardo L B CostaHyo S HanGary K KoskiBrian J CzernieckiPublished in: Journal for immunotherapy of cancer (2022)
BC.